MEDEXUS PHARMS INC - MEDXF STOCK NEWS

Medexus Pharmaceuticals (OTCQX: MEDXF) will host a conference call on February 10, 2022, at 8:00 AM ET to discuss its financial results for Q3 FY2022, ending December 31, 2021. The financial statements will be released after market close on February 9, 2022. Investors can participate via telephone or access a webcast through the company’s website. Medexus focuses on rare disease treatments, highlighting products like Rasuvo™ and IXINITY®, and plans to commercialize Treosulfan in the U.S. and Canada, currently under FDA review.

Medexus Pharmaceuticals announced that its CEO Ken d’Entremont and CFO Marcel Konrad will present at the H.C. Wainwright BioConnect 2022 Conference, occurring virtually from January 10-13, 2022. Their presentation will be available on-demand for attendees starting January 10 at 7:00 AM ET. Medexus focuses on innovative treatments for rare diseases with a strong North American platform, offering products such as Rasuvo™, IXINITY®, and Rupall®. More information about the conference and the webcast can be found on Medexus’ investor relations website.

Medexus Pharmaceuticals announced participation in two virtual investor conferences on December 8, 2021. CEO Ken d’Entremont and CFO Marcel Konrad will present at the **Sidoti December Micro Cap Virtual Conference** at 1:00 PM ET and later at the **SNN Network Canada Virtual Event** at 4:00 PM ET. Both presentations will be available for live streaming, with management also offering one-on-one meetings with qualified investors. Medexus focuses on innovative treatments for rare diseases and its product portfolio includes Rasuvo™, Metoject®, IXINITY®, and Rupall®.

Medexus Pharmaceuticals and medac GmbH have announced a timeline for the NDA resubmission of treosulfan to the FDA, expected in Q2 2022. This follows a productive Type A Meeting with the FDA, which confirmed that no additional Phase III study is required for approval. The FDA's decision on the NDA is anticipated within 2 to 6 months post-resubmission. Treosulfan, used in hematopoietic stem cell transplantation, is already available in Canada and Europe. Medexus continues to work with medac, which will fund regulatory costs until approval is granted.

Medexus Pharmaceuticals reported Q2 Fiscal 2022 financial results, achieving $17.9 million in revenue, a slight increase from $17.8 million year-over-year. This growth was largely driven by a 33% increase in unit demand for Rupall™, while IXINITY® sales continued to face challenges. Net income soared to $10.1 million, influenced by a non-cash unrealized gain on derivative fair value. However, Adjusted EBITDA decreased to ($2.0 million) due to rising R&D costs and investments related to treosulfan commercialization. The company is focused on improving IXINITY sales and expects continued growth.

Medexus Pharmaceuticals will present at the Q4 Investor Summit virtually on November 17, 2021, at 8:00 AM ET. CEO Ken d’Entremont and CFO Marcel Konrad will discuss the company’s innovative solutions in rare disease treatments. Interested investors can participate in one-on-one meetings throughout the conference. The summit connects small cap and microcap companies with over 800 investors, offering a platform to engage with potential stakeholders. For more details on the event and to register, visit www.investorsummitgroup.com.

Medexus Pharmaceuticals has appointed Ian C. Wildgoose Brown as the new general counsel and corporate secretary, effective immediately. With over a decade of legal expertise and experience in corporate transactions, he aims to strengthen the company’s commercial platform. Ken d’Entremont, CEO, expressed confidence in Wildgoose Brown's ability to contribute to growth through mergers and acquisitions. Medexus specializes in innovative treatments for rare diseases and holds a strong North American commercial presence.

Medexus Pharmaceuticals plans a conference call on November 11, 2021, at 8:00 AM ET to discuss its fiscal 2022 Q2 financial results ending September 30, 2021. Financial statements will be filed after the market closes on November 10, 2021. Investors can join via telephone or webcast. Medexus is recognized for its innovative treatments in rare diseases and aims for growth through its established product portfolio, including Rasuvo™, IXINITY®, and Rupall®.

Medexus Pharmaceuticals announced that the FDA granted a Type A meeting to medac GmbH for treosulfan, a drug intended for patients undergoing allogeneic hematopoietic stem cell transplantation. The meeting is scheduled for November 23, 2021. This follows a Complete Response Letter from the FDA received on August 3, 2021, regarding treosulfan's New Drug Application, indicating the need for additional data. CEO Ken d’Entremont expressed optimism about treosulfan's potential in the U.S. market, noting that the leading product, busulfan, achieved US$126M in sales before genericization.